Observational Study on the Effect of Switch to Lurasidone in Subjects With Schizophrenia"
NCT ID: NCT04312503
Last Updated: 2023-05-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
95 participants
OBSERVATIONAL
2020-07-13
2022-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison of Antipsychotics for Metabolic Problems in Schizophrenia or Schizoaffective Disorder
NCT00423878
Metabolic Profile and Anthropometric Changes in Schizophrenia
NCT00534183
Effect of Calories and Fat Content on the Pharmacokinetics of Lurasidone HCl
NCT01074632
A Study of Subjects Switched to Lurasidone for the Treatment of Schizophrenia or Schizoaffective Disorder
NCT01143090
Lurasidone Vs Olanzapine on Neurotrophic Biomarkers and Cardiometabolic Parameters in Unmedicated Schizophrenia
NCT03304457
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
COHORT A: Lurasidone
Patients treated with Lurasidone
Lurasidone
Patients are treated with dosages according clinical practice
COHORT B: aripiprazole, olanzapine, quetiapine or risperidone)
Patients treated with other atipical antypsicothic as aripiprazole, olanzapine, quetiapine or risperidone)
aripiprazole, olanzapine, quetiapine or risperidone
Patients are treated with dosages according clinical practice
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lurasidone
Patients are treated with dosages according clinical practice
aripiprazole, olanzapine, quetiapine or risperidone
Patients are treated with dosages according clinical practice
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients who gave their written consent for participation in the study and for personal data processing and willing to comply with all study procedures.
* Male and female patients ≥ of 18 years old at baseline.
* Patients treated or in treatment with any typical or atypical antipsychotic monotherapy or polytherapy.
* Patients switched from the pre-existing therapy to lurasidone, aripiprazole, olanzapine, quetiapine or risperidone in monotherapy within the preceding 2 weeks. The date of the switch is considered as baseline.
Exclusion Criteria
* Patients fulfilling DSM-5 criteria for diagnosis of bipolar disorder and/or dementia.
* Amphetamines and/or Opiates abuse or dependence , as defined by DSM-5 criteria.
* Patients with no history of antipsychotics use.
* Patients recruited in another study as follows:
* currently enrolled in any pharmacological or non-pharmacological, interventional or observational study:
* who participated in the last 30 days to any observational or no-profit interventional study;
* who participated in the last 12 months to any interventional commercially sponsored study.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Aziende Chimiche Riunite Angelini Francesco S.p.A
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ospedali Riuniti SOD di Clinica Psichiatrica
Ancona, AN, Italy
Spedali Civili di Brescia Dipartimento di Salute Mentale 1
Brescia, BS, Italy
A.O.U. di Cagliari Corso Vittorio Emanuele II, 6 09124 Cagliari (CA)
Cagliari, CA, Italy
P.O. Gaspare Rodolico - U.O.C. di Psichiatria
Catania, CT, Italy
AO Mater Domini U.O. Psichiatria
Catanzaro, CZ, Italy
A.O.U. Ospedali Riuniti di Foggia - S.P.D.C. Viale Pinto 71121 Foggia (FO)
Foggia, FG, Italy
IRCCS Ospedale Policlinico San Martino
Genova, GE, Italy
DSM Dipartimento Salute Mentale
Lecce, LE, Italy
Ospedale S. Gerardo Università Bicocca Dipartimento di Salute Mentale
Monza, MB, Italy
Ospedale Maggiore Policlinico di Milano U.O. C. di Psichiatria
Milan, MI, Italy
Ospedale San Raffaele U.O.C. Psichiatria Generale e Riabilitazione
Milan, MI, Italy
Ospedale Luigi Sacco, S.C. Psichiatria 2
Milan, MI, Italy
III S.P.D.C. Azienda Ospedaliera di Padova 35128 Padova - (PD)
Padua, PD, Italy
Clinica Von Sibenthal Via della Madonnina, 1
Genzano di Roma, RM, Italy
Azienda Ospedaliero Universitaria Sant'Andrea
Roma, RM, Italy
A.O.U. San Luigi Gonzaga - S.C.D.U. di Psichiatria Regione Gonzole, 10
Orbassano, TO, Italy
Azienda Ospedaliera Universitaria Federico II - U.O. Psichiatria
Napoli, , Italy
Azienda Ospedaliera - Universitaria Senese
Siena, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
151(A)PO18531
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.